Why Are Analysts So Bullish on Cybin?


Ryan Allway

May 6th, 2021

App, Exclusive, Psychedelics, Top Story


The global psychedelics market is projected to grow from $4.75 billion to $10.75 billion by 2027, according to Research and Markets, representing a strong 12.36% compound annual growth rate. With more than 40 public companies in the psychedelics sector and an exchange-traded fund, there is no shortage of opportunities for investors interested in the space.

Cybin Corp. (NEO: CYBN) (OTCQB: CLXPF) is one of the largest psychedelic companies with a market capitalization of around C$300 million. With a robust development pipeline and patent portfolio, the company is well-positioned to bring unique therapeutics that will target major depressive disorder, alcohol use disorder, and other conditions. 

Let’s take a look at what analysts are saying about the company, why they’re so bullish on the stock and the upcoming catalysts investors should keep an eye on.

What Analysts Say About Cybin

There are three analysts covering Cybin with price targets ranging from C$8.00 to C$11.00 per share—a significant premium to the current share price hovering around C$2.00. 

Canaccord Genuity – Target: C$8.00 – Canaccord Genuity analysts believe that newly published results from the Psilodep-RCT study in the New England Journal of Medicine are encouraging for the use of psilocybin in the depression setting. The analysts believe that the company’s Phase 2a clinical trial designed to find optimal dosages of CYB001 for major depressive disorder could be a key catalyst in light of the Psilodep-RCT results.

Stifel Nicolaus – Target: C$11.00 – Stifel Nicolaus analysts note the rapid progression in developing novel psychedelic molecules, transforming it from a single molecule strategy to one with stronger IP opportunities. The analyst recently raised its price target from C$5.00 to C$11.00 to reflect the development of CYB003, a second-generation tryptamine that has already undergone proof-of-concept studies and isn’t reflected in the share price.

Roth Capital – Target: US$10.00 – Roth Capital analysts believe that Cybin has found ingenious ways to improve potency and delivery of psychedelic drugs with reformulation and by exploring deuterated analogues. In light of an Imperial College of London study showing that psychedelics may outperform SSRIs, the analyst believes that the company’s flagship clinical trial could see success when paired with the innovative delivery mechanisms. 

What Analysts Are Watching Ahead

Cybin has several upcoming catalysts that could influence the stock price over the coming years, including its Phase 2a clinical trial targeting major depressive disorder. In addition to company-specific catalysts, analysts will also be keeping an eye on industry-wide events that could have a meaningful impact on the stock, such as other clinical trial results.

The three most significant upcoming catalysts include:

  • U.S. Up-Listing – Q2 2021 – Cybin plans to up-list to an unspecified major U.S. exchange, which could expand its shareholder base into the United States.
  • Phase 2a Clinical Trial – Mid 2021 – Cybin plans to initiate its Phase 2a study of sublingual films for CYB001 in Q2 2021 and complete the trial by mid-2021 while its global Phase 2b study could begin by the end of 2021.
  • Tryptamine Candidate – End of 2021 – Cybin hopes to start trials for its tryptamine-based CYB003 by the end of 2021 with a second candidate, CYB004, by 1H 2022.

Looking Ahead

Cybin Corp. (NEO: CYBN) (OTCQB: CLXPF) is one of the largest companies in the psychedelics space with a robust clinical pipeline and IP portfolio. With analysts bullish on the company’s future, investors may want to keep an eye on the stock ahead of several upcoming catalysts, including a U.S. up-listing, its Phase 2a clinical trial results, and a tryptamine candidate.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading